2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1434

COX-2 Inhibitor Contributes Cell Death in Rheumatoid Arthritis Fibroblast-like Synoviocytes Via PI3K/AKT/mTOR Signaling Pathway Triggered By Autophagy
Abstract Number: 408

CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Abstract Number: 216

Creation of the First Massive Open Online Course for Patients with Rheumatoid Arthritis
Abstract Number: 2775

Critical Role of Neutrophil Extracellular Traps (NETs) in Patients with Behcet’s Disease
Abstract Number: 951

Cross Sectional Analysis of Citrullinated-Synovial Antigen-Specific CD4+ T Cells in an RA Cohort Demonstrates Antigen Based Differences in T Cell Frequency, Phenotype and the Influence of Immunotherapy
Abstract Number: 2837

Cross-Sectional Analysis of Chikungunya Arthritis Patients 22-Months Post-Infection Demonstrates a Lack of Viral Persistence in Synovial Fluid
Abstract Number: 1950

Cross-Sectional Analysis of Foot Osteoarthritis Frequency and Associated Factors: The Johnston County Osteoarthritis Project
Abstract Number: 1323

Crucial Roles for Toll-like Receptor 9 in the Pathogenesis of Erosive Autoimmune Arthritis and during Osteoclastogenesis
Abstract Number: 1942

CTLA4-Ig Directly Inhibits Osteoclast Generation from Human Peripheral Monocytes and Tumor Necrosis Factor α-Treated Inflammatory Monocytes
Abstract Number: 2992

Curbing the Opioid Epidemic: Predictors of Opioid Use in Juvenile Fibromyalgia Syndrome
Abstract Number: 2321

Current Practices and New Directions in Occupational and Physical Therapy for Children with Rheumatic Diseases in the Biologic Era
Abstract Number: 2533

Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Abstract Number: 897

Cutaneous Lupus Is Driven By an Exaggerated Interferon Kappa Loop Which Primes for Interferon Alpha Responses
Abstract Number: 2710

CXCR3+CCR6+CD4+ T Cells (Th1Th17) and RF As Novel Predictive Markers for Clinical Response to Abatacept Treatment in Patients with Rheumatoid Arthritis: The 52-Week Analysis
Abstract Number: 1734

CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].